Biohaven Ltd BHVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Biohaven Announces Scientific Leadership Transitions
-
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
-
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
-
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
-
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
-
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
-
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
-
Biohaven Shares Slide Premarket After FDA Rejects Vyglxia
Trading Information
- Previous Close Price
- $14.17
- Day Range
- $13.62–15.51
- 52-Week Range
- $7.48–18.57
- Bid/Ask
- $14.90 / $15.88
- Shares Outstanding
- 150.56M
- Market Cap
- $2.32B
- Volume/Avg
- 4M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 274
- Website
- https://www.biohaven.com
Valuation
|
Metric
|
BHVN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 16.47 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BHVN
|
|---|---|
Quick Ratio | 6.68 |
Current Ratio | 7.41 |
Interest Coverage | — |
Quick Ratio
BHVN
Profitability
|
Metric
|
BHVN
|
|---|---|
Return on Assets (Normalized) | −126.62% |
Return on Equity (Normalized) | −529.67% |
Return on Invested Capital (Normalized) | −167.08% |
Return on Assets
BHVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|g$x%SQ | LOCK|pB@?? | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|JC!CB% | LOCK|ss@? | $70B | |||
| argenx SE ADR
ARGX
| LOCK|B#FcmBc | LOCK|mf | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^KqTDD | LOCK|?Y$> | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|g%>M@?? | LOCK|!n@ | $37B | |||
| Moderna Inc
MRNA
| LOCK|$WXc>@^ | LOCK|Bg^ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@BDd%!%^ | LOCK|hJXDx | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|tTzw>%r | LOCK|g&V | $23B | |||
| Incyte Corp
INCY
| LOCK|Cpv^$c | LOCK|$QW | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%rk<>^ | LOCK|%!^ | $16B |
United States